Business Description
Sanofi SA
ISIN : US80105N1054
Share Class Description:
STU:SNW2: ADRTotal Employee Number:
74,846Compare
Compare
Traded in other countries / regions
SAN.FranceSNY.USA0O59.UKSNW.Germany1SAN.ItalySAN1N.MexicoSNY.CanadaSANO.AustriaSNW.BulgariaSAN.Switzerland IPO Date
2012-07-24Description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.27 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.34 | |||||
Debt-to-EBITDA | 1.82 | |||||
Interest Coverage | 13.8 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 1.54 | |||||
Beneish M-Score | -2.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.7 | |||||
3-Year EBITDA Growth Rate | -1.8 | |||||
3-Year EPS without NRI Growth Rate | -2.9 | |||||
3-Year FCF Growth Rate | -4.2 | |||||
3-Year Book Growth Rate | -0.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 7.23 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.16 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.3 | |||||
9-Day RSI | 43.32 | |||||
14-Day RSI | 46.05 | |||||
3-1 Month Momentum % | -6.06 | |||||
6-1 Month Momentum % | -6.06 | |||||
12-1 Month Momentum % | -9.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.99 | |||||
Quick Ratio | 0.64 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 282.72 | |||||
Days Sales Outstanding | 62.01 | |||||
Days Payable | 197.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 5.63 | |||||
Dividend Payout Ratio | 0.68 | |||||
3-Year Dividend Growth Rate | 5.6 | |||||
Forward Dividend Yield % | 5.63 | |||||
5-Year Yield-on-Cost % | 6.71 | |||||
3-Year Average Share Buyback Ratio | 1.4 | |||||
Shareholder Yield % | 5.68 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.77 | |||||
Operating Margin % | 20.6 | |||||
Net Margin % | 8.09 | |||||
EBITDA Margin % | 26.46 | |||||
FCF Margin % | 17.22 | |||||
OCF Margin % | 24.2 | |||||
ROE % | 5.64 | |||||
ROA % | 3.12 | |||||
ROIC % | 6.81 | |||||
3-Year ROIIC % | -12.01 | |||||
ROC (Joel Greenblatt) % | 53.63 | |||||
ROCE % | 6.34 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 22.77 | |||||
Forward PE Ratio | 8.88 | |||||
PE Ratio without NRI | 12.29 | |||||
Shiller PE Ratio | 12.87 | |||||
Price-to-Owner-Earnings | 8.61 | |||||
PS Ratio | 1.85 | |||||
PB Ratio | 1.29 | |||||
Price-to-Tangible-Book | 99.83 | |||||
Price-to-Free-Cash-Flow | 10.76 | |||||
Price-to-Operating-Cash-Flow | 7.66 | |||||
EV-to-EBIT | 17.33 | |||||
EV-to-Forward-EBIT | 10.08 | |||||
EV-to-EBITDA | 8.25 | |||||
EV-to-Forward-EBITDA | 8.3 | |||||
EV-to-Revenue | 2.18 | |||||
EV-to-Forward-Revenue | 2.09 | |||||
EV-to-FCF | 12.68 | |||||
Price-to-GF-Value | 0.69 | |||||
Price-to-Graham-Number | 7.39 | |||||
Earnings Yield (Greenblatt) % | 5.77 | |||||
FCF Yield % | 9.44 | |||||
Forward Rate of Return (Yacktman) % | 2.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Sanofi SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 48,919 | ||
| EPS (TTM) (€) | 1.635 | ||
| Beta | 0.4354 | ||
| 3-Year Sharpe Ratio | -0.49 | ||
| 3-Year Sortino Ratio | -0.61 | ||
| Volatility % | 18.09 | ||
| 14-Day RSI | 46.05 | ||
| 14-Day ATR (€) | 1.016177 | ||
| 20-Day SMA (€) | 38.18 | ||
| 12-1 Month Momentum % | -9.71 | ||
| 52-Week Range (€) | 35.6 - 45 | ||
| Shares Outstanding (Mil) | 2,396.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sanofi SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sanofi SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-01-29 08:30 | In 182 days | ||
| Fourth quarter earnings results for 2026 | 2027-01-29 | In 181 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 | In 90 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 90 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 07:00 | 39.20 (-1.51%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 39.20 (-1.51%) | ||
| USD 2.418953 Cash Dividend | 2026-05-04 | 39.60 (+0.00%) | ||
| General meeting for 2026 | 2026-04-29 | 39.20 (+0.51%) | ||
| First quarter earnings conference call for 2026 | 2026-04-23 07:00 | 40.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 40.00 (+0.00%) |
Show
Entries
Sanofi SA Frequently Asked Questions
What is Sanofi SA(STU:SNW2)'s stock price today?
The current price of STU:SNW2 is €37.40. The 52 week high of STU:SNW2 is €45.00 and 52 week low is €35.60.
When is next earnings date of Sanofi SA(STU:SNW2)?
The next earnings date of Sanofi SA(STU:SNW2) is 2026-10-30.
Does Sanofi SA(STU:SNW2) pay dividends? If so, how much?
The Dividend Yield % of Sanofi SA(STU:SNW2) is 5.63% (As of Today), Highest Dividend Payout Ratio of Sanofi SA(STU:SNW2) was 0.79. The lowest was 0.49. And the median was 0.65. The Forward Dividend Yield % of Sanofi SA(STU:SNW2) is 5.63%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Sanofi SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers